局部晚期咽癌与喉癌根治性或辅助放疗的性别差异
本研究回顾性分析了2016至2023年间309例(男性246例、女性63例)接受根治性放疗的口咽、喉或下咽鳞癌患者,比较性别在生存、毒性和局部复发模式上的差异。结果显示男女OS、PFS、MFS无显著差异,但女性≥3级皮炎发生率更高(12.7% vs. 5.3%,p=0.037),且A型淋巴结失败在女性中更常见(64.3% vs. 28.8%,p=0.014)。结论认为性别非独立生存预测因子,但女性严重皮肤毒性和淋巴结失败率较高提示需性别适配的放疗策略。
要点
- 男女患者OS、PFS、MFS无显著差异
- 女性≥3级皮炎发生率显著高于男性(12.7% vs. 5.3%,p=0.037)
- 女性A型淋巴结失败率显著高于男性(64.3% vs. 28.8%,p=0.014)
核心结论
- 性别不是该局部晚期头颈鳞癌队列的独立生存预测因子。
- 女性严重皮肤毒性和A型淋巴结失败率更高,提示需性别适配放疗策略。
研究设计与样本
- 回顾性 review,纳入309例原发口咽、喉或下咽鳞癌患者(男246例,女63例)。
- 患者于2016至2023年在本机构接受根治性放疗,纳入标准为组织学确诊鳞癌、T3/T4和/或淋巴结阳性、完成放疗且随访充分。
主要发现
- 所有治疗亚组中男女OS、PFS、MFS均无显著差异。
- Log rank检验未发现生存和局部复发的显著预后因素。
- 女性≥3级皮炎发生率为12.7%,男性为5.3%(p=0.037)。
- 女性A型(中央高剂量区)淋巴结失败率为64.3%,男性为28.8%(p=0.014)。
- 其他复发模式无显著性别差异。
关键数值与推荐
- 局部失败分型采用五型系统:A中央高剂量、B周边高剂量、C中央中或低剂量、D周边中或低剂量、E剂量外。
- A型淋巴结失败女性64.3% vs. 男性28.8%(p=0.014)。
- ≥3级皮炎女性12.7% vs. 男性5.3%(p=0.037)。
临床怎么用
- 对女性局部晚期头颈鳞癌放疗患者应加强皮肤毒性监测与管理。
- 女性患者淋巴结失败以中央高剂量区为主,放疗靶区设计时需关注该区域覆盖。
局限性
- 本研究为单中心回顾性 review,样本量有限(女性仅63例)。
- 未报告前瞻性验证,性别适配策略需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate sex-based differences in survival outcomes, toxicity, and patterns of local recurrence in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive or adjuvant radiotherapy (RT). METHODS: We conducted a retrospective review of 309 patients (246 males, 63 females) diagnosed with primary squamous cell carcinoma of the oropharynx, larynx, or hypopharynx treated with curative-intent RT at our institution between 2016 and 2023. Inclusion criteria comprised histologically confirmed SCC, stage T3/T4 and/or node-positive disease, and complete RT treatment with adequate follow-up. Survival endpoints-overall survival (OS), progression-free survival (PFS), and metastasis-free survival (MFS)-were analyzed using the Kaplan-Meier method and log-rank tests. Patterns of local failure were classified using an established five-type system: A (central high-dose), B (peripheral high-dose), C (central intermediate- or low-dose), D (peripheral intermediate- or low-dose), and E (extraneous dose). Treatment-related toxicity was also compared between sexes. RESULTS: No significant differences in OS, PFS, or MFS were found between male and female patients across all treatment subgroups. Log rank test did not identify any significant prognostic factor for survival and local recurrence. However, female patients experienced a higher rate of grade ≥ 3 dermatitis (12.7% vs. 5.3%, p = 0.037). Pattern A nodal failures (central high-dose volume) were significantly more common in females (64.3%) than in males (28.8%; p = 0.014), while other recurrence patterns showed no significant sex-based differences. CONCLUSION: Sex was not an independent predictor of survival in this cohort of locally advanced HNSCC patients. Nevertheless, the higher rate of severe skin toxicity and nodal failures in females highlights a potential need for sex-adapted radiotherapy strategies and further prospective investigation. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Agolli L, Reinhard L, Gawish A, et al. Sex-based differences in patients with locally advanced pharyngeal and laryngeal SCC treated with definitive or adjuvant radiotherapy. Radiat Oncol. 2025. PMID: 41345688. doi:10.1186/s13014-025-02771-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。